Biologics are complex medications produced through biological processes or from living organisms such as proteins and genes. Biosimilars are what they sound like — similar to, but not the same as, an ...
In the fourth part of our FDA: Drug & Device Team’s series on biological products regulation, we discuss the Food and Drug Administration’s requirements and standards for approval of biosimilar ...
The Inflation Reduction Act (IRA) has reshaped how Medicare covers and reimburses prescription drugs. For the first time, the federal government established prices for ten drugs selected through the ...
The Food and Drug Administration (FDA) is launching an effort to streamline the approval process for cheaper alternative “biosimilar” versions of biologic drugs as a way to curb health costs. The ...
Biologic drugs, made from living organisms and usually taken by injection or infusion, are expensive treatments for complex chronic conditions such as cancer and autoimmune diseases. Biosimilars, ...
SEATTLE--(BUSINESS WIRE)--Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, today announced the closing of a $16 million Series B ...
This article originally appeared on PolitiFact. If you watch TV and don't mute ads, you've probably heard of a few biologics. They're drugs such as Humira for arthritis and Trulicity for Type 2 ...
The FDA recently designated Yuflyma as "interchangeable" with the popular biologic Humira for the treatment of Crohn's disease and ulcerative colitis, two types of inflammatory bowel disease (IBD), ...
Biologic drugs are a newer treatment option for chronic rhinosinusitis with nasal polyps. They work differently from other treatments. Nasal polyps are small, noncancerous growths that develop in the ...
Everyday Health on MSN
Is stacking biologics safe if you have Crohn’s disease?
It’s becoming more common to treat Crohn’s disease with 2 biologic medications, or a biologic and a small molecule drug. Find ...
After raising nearly $90 million in its recent public offering, Vancouver-based Absci is advancing toward clinical trials for what would be its first biologic drug candidate. Absci uses its database ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results